Objective Patients who have received transplants generally require life-long immunosuppressive drugs, which are all associated with potentially life- threatening adverse effects. Occasionally, "tolerant" patients have been able to stop these drugs without losing their grafts, but we cannot differentiate them from others in whom stopping these drugs will result in rejection. In this project, specimens will be collected from tolerant patients and used in a series of novel, tests of immunological reactivity which have been developed by the consortium. An adequate number of such rare patients could only be collected from within a very large population, necessitating a collaboration of this size. We predict that this will reveal a tolerant "fingerprint' which can then be used to identify those whose drugs can be stopped and to define drug protocols which can induce tolerance. Programme(s) FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002 Topic(s) 1.1.1.-3. - Key action The "Cell factory" Call for proposal Data not available Funding Scheme DEM - Demonstration contracts Coordinator CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES EU contribution No data Address Boulevard Jean Monnet 30 44035 NANTES France See on map Total cost No data Participants (4) Sort alphabetically Sort by EU Contribution Expand all Collapse all HUMBOLDT-UNIVERSITAET BERLIN Germany EU contribution No data Address Schumannstrasse 20-21 10117 BERLIN See on map Total cost No data MEMOREC BIOTEC GMBH Germany EU contribution No data Address Stoeckheimer Weg 1 50829 KOELN See on map Total cost No data THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD United Kingdom EU contribution No data Address John Radcliffe Hospital OX3 9DU OXFORD See on map Total cost No data Universite Libre de Bruxelles Belgium EU contribution No data Address Avenue Franklin Roosevelt 50 BRUXELLES See on map Links Website Opens in new window Total cost No data
